Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.
The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc.
IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 31, 24 | -0.53 Decreased by -8.16% | -0.51 Decreased by -3.92% |
| Feb 20, 24 | -0.52 Decreased by -4.00% | -0.47 Decreased by -10.64% |
| Nov 7, 23 | -0.46 Decreased by -1.25 K% | -0.49 Increased by +6.12% |
| Aug 10, 23 | -0.50 Increased by +12.28% | -0.56 Increased by +10.71% |
| May 9, 23 | -0.49 Decreased by -36.11% | -0.55 Increased by +10.91% |
| Mar 7, 23 | -0.50 Decreased by -6.38% | -0.56 Increased by +10.71% |
| Nov 8, 22 | 0.04 Increased by +112.90% | -0.62 Increased by +106.45% |
| Aug 15, 22 | -0.57 Decreased by -72.73% | -0.52 Decreased by -9.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 8.04 M Decreased by -72.94% | -27.44 M Decreased by -1.17 K% | Decreased by -341.38% Decreased by -4.04 K% |
| Jun 30, 23 | 3.54 M Decreased by -39.43% | -27.93 M Decreased by -29.21% | Decreased by -787.98% Decreased by -113.32% |
| Mar 31, 23 | 7.88 M Decreased by -30.63% | -20.04 M Decreased by -11.40% | Decreased by -254.33% Decreased by -60.58% |
| Dec 31, 22 | 4.02 M Increased by +35.74% | -21.96 M Decreased by -20.57% | Decreased by -545.97% Increased by +11.17% |
| Sep 30, 22 | 29.70 M Increased by +230.87% | 2.57 M Increased by +122.19% | Increased by +8.65% Increased by +106.71% |
| Jun 30, 22 | 5.85 M Decreased by -33.18% | -21.61 M Decreased by -97.43% | Decreased by -369.39% Decreased by -195.46% |
| Mar 31, 22 | 11.36 M Increased by +56.74% | -17.99 M Decreased by -99.42% | Decreased by -158.38% Decreased by -27.23% |
| Dec 31, 21 | 2.96 M Decreased by -71.97% | -18.21 M Decreased by -254.66% | Decreased by -614.65% Decreased by -1.17 K% |